Transfer of the Pharmaceutical Business to Shionogi & Co., Ltd. and Sale of Shares in Torii Pharmaceutical Co., Ltd.
First written in FY2025-H1. 1 of 2 entries say "Achieved", first in FY2025. Latest entry: FY2025.
1 other company's latest entry also says "Achieved".
- FY2025AchievedAnnual report
「“The absorption-type company split was subsequently completed on 1 December 2025.” “The share transfer was subsequently completed on 1 September 2025.”」
The absorption-type company split transferring the pharmaceutical business to Shionogi & Co.,Ltd. and the transfer of the shares in Torii Pharmaceutical were each completed. The transfer price was stated as ¥42,811 million. - FY2025-H1First statedAnnual report
「At a meeting of the Board of Directors held on 7 May 2025, our company resolved to transfer its pharmaceutical business to Shionogi & Co.,Ltd. through a company split (simplified absorption-type company split) and entered into an agreement relating to the absorption-type company split. The effective date of the absorption-type company split is scheduled for December 2025, and the consideration to be received by our company for the rights and obligations transferred to Shionogi & Co.,Ltd. is ¥5,397 million (scheduled). At the same Board meeting, our company also resolved to enter into an agreement with Shionogi & Co.,Ltd. relating to the tender offer under which (1) our company will not tender any of its shares in Torii Pharmaceutical Co., Ltd., our consolidated subsidiary, in the tender offer to be conducted by Shionogi & Co.,Ltd. for Torii Pharmaceutical’s common shares, (2) following the successful completion of the tender offer, procedures will be carried out to make our company and Shionogi & Co.,Ltd. the only shareholders of Torii Pharmaceutical, and (3) our company will transfer its shares in Torii Pharmaceutical to Torii Pharmaceutical through the acquisition of treasury shares by Torii Pharmaceutical, among other matters, and entered into the agreement relating to the tender offer. The execution date of the share transfer is scheduled for September 2025, and the transfer price is ¥70,342 million (scheduled).」
A plan was announced to transfer the pharmaceutical business to Shionogi & Co.,Ltd. through a company split and transfer the shares in Torii Pharmaceutical through the acquisition of treasury shares and other measures. The scheduled effective date, share transfer execution date, consideration and transfer price were specified.